Ben Around

ISIS' Short-Term Trends Demonstrate When Technical Analysis Is Important

I have been in and out of isis for years, hoping for a buy out. But now because of the many partners they have I look forward to making money with new partners in some of the pipeline drugs in Phase II & III.

In addition I believe they are pursuing a correct strategy of developing some drugs for release with them receiving a higher % of the profits.

I am buying on pull backs.

Short Interest Rises as Nokia Battles Interdigital, Apple

I thought the Nokia patent issue is not even factored into the earnings projections of IDCC. So it seems premature for the shorts to sell this down to these levels. I can't understand the concern, so I bought at 19.

Vonage Launches Mobile Apps, Focusing on International Calls

Superficial article.

I expect a lot more info from a tech writer.

Is it a free service from VG?
What does it cost?
How does it work?

FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG

CYTR has the potential to fly, because there is little notice of the secondary use of arimoclomol in treating stroke victims up to 48 hours after the initial stroke.

The stroke treatment possibilities and the 45% stake in RXII are the reason I am very long on this stock.

Do your own DD.

"Arimoclomol is an orally administered molecular chaperone regulator drug candidate that is being considered as a treatment for ALS and stroke recovery. Molecular chaperone regulator drugs are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of “molecular chaperones.” Molecular chaperones detect proteins that are misfolded, and have the ability to refold those proteins into the appropriate, non-toxic shape.

In February 2009, CytRx announced the commencement of a Phase 2/3 adaptive clinical trial, sponsored by the ALS Association and the FDA’s Office of Orphan Products Development OOPD, to study arimoclomol in a subset of patients with the inherited or familial form of ALS. In March 2009, the Company reported that arimoclomol had demonstrated statistically significant neurorestorative results in a preclinical embolic stroke trial. This data supported previous preclinical results indicating improvement in stroke recovery following oral arimoclomol administration up to 48 hours post-stroke."

See the article @
finance.yahoo.com/news...

Zix: Prescription for Divestiture?

They are at least showing iniative in developing or unloading the business that is not performing to expectations. The business model they have chosen still shows they know what they have to do to compete in the tough eRx market. The plan to get providers to shoulder the expense of implementation was and may still be a viable plan. But the current market conditions make it tough for the expansion of the business with the providers under pressure themselves to perform.

Perhaps some deep pocket company looking to enter the market will find them interestng.

Zix Corporation Close to Securing Profits

There is a lot of potential for this company.
But we need the officers to get out and do the talking.
They don't seem to get it about P.R. for a company.

I think the best bet for us, longs, is for the company to put themselves on the market.

Google, microsoft, yahoo are our market.

Let's Hope the Auto Bailout Has Failed for Good

Just what we need; legislation to set wages for jobs.
$17 for auto workers in 90 days.

These free market guys now want to set wages
(Pixxed off lame duck senators.)

They have to get even with the unions somehow.

3 Lower Risk Stocks: Pfizer, Analog Devices, Chevron

I just got the jewish language version, I think.

It's Official: Renewable Energy Tax Credits Here to Stay

Someone forgot to tell Goldman;

Solar: Goldman Turns Cautions; Fears Over Supply; Spreading Concerns On Impact Of Tight Credit
Posted by Eric Savitz
Solar stocks are trading sharply lower this morning after Goldman Sachs analyst Michael Molnar declared he has become cautious on the solar group, “as less generous subsidies combined with a wave of supply pose a real risk.”

Molnar asserts in a research note that the risk of oversupply in the solar market “will soon become a reality as considerably less generous demand subsidies take hold just as a wave of supply and tight financing hit the market.” He thinks that “liberal subsidies of the past in markets like Germany and Spain are unlikely to be replicated in the future givne fears of their ultimate cost in a bad world economy.”

As supply increases, he contends, prices will have to “adjust strongly downward to generate demand.” He thinks that trend will lead to below-consensus estimates for module manufacturers and compressed valuations for stocks in the sector.

Molnar today cut his rating on First Solar to a Conviction Sell from Buy, slashing his price target to $103 from $365. For SunPower (SPWRA) he goes to Sell from Buy, with a target of $43, down from $100. He also cuts his target on Evergreen Solar (ESLR) to $4.50 from $10.50.

He sharply reduced estimates for all three of those companies. For FSLR, he now sees $3.62 next year, and $5.92 in 2010, down from $3,75 and $7.13. For SPWRA, he sees $1.22 and $2.47, down from $1.27 and $2.63. For ESLR, he goes to $1.64 and $2.92, down from $1.72 and $2.87.

Time to Buy Elan?

I think the market over reacted to bad news and it is time to buy below 11.

Watch for More Coming Biotech Acquisitions

The writer failed to mention Elan. The recent bad news has pounded the PPS to a rediculous $10 that makes them a easy target for a tokeover. I would bet, I am buying at this level, that we will see a bid from BIIB to get Elan on the cheap.

Ichan wants to get BIIB to sell themselves but if they owned all of Elan they would be a much stronger company.

Elan, Wyeth's Alzheimer Drug News Doesn't Please Investors

The market reacted like elan is done. The MS drug continues to grow. The crohn disease treatment is not approved or disproved yet.

I think at 19 this is a buy again.

Ford Shareholders Face High Potential for Pain

The writer failed to mention his position in Ford stock. I assume he is short.

He failed to include the class B shares held by the family and the fact that a bankruptcy would wipe them out. He also forgot about the 6.5 mil shares held by Kerkorian.

I look at Ford as a long term buy with a very low probability of a chapter 11. The issue is to find a good entrypoint. I would expect to see F test the 4.5 point in the future and that would be a good time to buy and hold.

InterDigital/Samsung ITC Case: Waiting for a Decision

The market reaction to any negative news must be looked at and reviewed in light of past performance. In this case I believe that this drop is a buying op and should be acted on. This company below 20 is a buy.

Just my opinion. I have been wrong before. But I did buy on Tuesday.

Immunogen and Seattle Genetics: Verging on an Inflection Point

Very interesting article.
I have been in and out of imgn for years and watch it track from 3-6, usually with some justification of the price variations from external influences.
This latest drop on tuesday (June 3) completely baffles me. I look at it as a buy in again opportunity since I can't see any other reason other than small investor interest.

Any in comments on Tuesday's action?